Abstract
Background This study aims to describe the epidemiological trends and estimate the economic burden of genital warts (GW) in Dutch primary care.
Methods A retrospective, non-interventional, multiyear study (2011-2021) was performed using data from the Nivel Primary Care Database. Changes in incidence by age group, sex, and level of urbanisation of individuals with GW and associated healthcare resource use (general practitioner consultations, prescribed medication, and referrals) were estimated over the 11-year period. Total annual healthcare costs and cost per incident case were estimated via a bottom-up gross costing approach.
Results Between 2011 and 2021, GW incidence increased, which was especially seen in men (from 2.0 to 3.5 per 1 000 inhabitants) and to a lesser extent in women (from 1.9 to 2.1 per 1 000 inhabitants). GW incidence was most common in age group 20-29 years (men: 43.6%; women: 50.7%) and highly urbanised areas. Medication was prescribed in 61.4% of GW cases, and 5.4% of GW patients were referred to secondary care. Total costs in Dutch primary care increased by 108% from EUR 2.3 million in 2011 to EUR 4.9 million in 2021. The cost per incident case also showed an increasing trend from EUR 72 in 2011 to EUR 99 in 2021. Referrals to secondary care resulted in a 14-30% increase of total costs.
Conclusions This study provides novel insights into recent epidemiological trends of GW and its associated costs in Dutch primary care. Incidence especially increased among men and total annual costs of GW in primary care doubled between 2011 and 2021.
Competing Interest Statement
CV, JB, and LJ do not report any conflicts of interest. CD is an employee of MSD the Netherlands who may own stock and/or hold stock options in in Merck & Co., Inc., Rahway., NJ, USA. MJP reports grants and honoraria from various pharmaceutical companies, inclusive those potentially interested in the subject matter of this paper.
Funding Statement
This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The retrospective analysis was conducted based on aggregate data obtained from the Netherlands Institute for Health Services Research (Nivel) Primary Care Database containing no directly identifiable data, and therefore, according to Dutch legislation, neither informed consent from study subjects nor approval by a medical ethics committee is obligatory, (art. 24 General Data Protection Regulation (GDPR) Implementation Act jo art. 9.2 sub j GDPR). Patient-level data was stored and handled by Nivel in accordance with their guidelines. To protect the privacy of individual patients, healthcare professionals, and providers such as hospitals and primary care practices, an agreement on the handling of data was signed by all researchers. In the privacy regulations for the Primary Care Database, Nivel states what data are collected, how they are managed and what the rights of registered participants are. GDPR is adhered to. Steering committees with representatives from national associations of healthcare providers take part in the decision-making process of the use of data. This study was approved by the relevant governance bodies of the Nivel Primary Care Database (nr. NZR00322.032).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Conflict of interest: CV, JB, and LJ do not report any conflicts of interest. CD is an employee of MSD the Netherlands who may own stock and/or hold stock options in in Merck & Co., Inc., Rahway., NJ, USA. MJP reports grants and honoraria from various pharmaceutical companies, inclusive those potentially interested in the subject matter of this paper.
Data Availability
All data produced in the present work are contained in the manuscript
